A. Bois, M. Quinn, T. Thigpen, J. Vermorken, E. Avall-lundqvist et al., Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR), consensus statements on the management of ovarian cancer: final document of the 3rd International gynecologic cancer intergroup ovarian cancer consensus conference, pp.93-96, 2004.
DOI : 10.1093/annonc/mdj032

R. Bristow, R. Tomacruz, D. Armstrong, E. Trimble, and F. Montz, Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis, Journal of Clinical Oncology, vol.20, issue.5, pp.1248-1259, 2002.
DOI : 10.1200/JCO.2002.20.5.1248

. International-collaborative-ovarian-neoplasm and . Group, Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial, Lancet, vol.360, pp.505-515, 2002.

R. Ozols, B. Bundy, B. Greer, J. Fowler, D. Clarke-pearson et al., Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study, Journal of Clinical Oncology, vol.21, issue.17, pp.3194-3200, 2003.
DOI : 10.1200/JCO.2003.02.153

R. Young, Early-Stage Ovarian Cancer: To Treat or Not To Treat, JNCI Journal of the National Cancer Institute, vol.95, issue.2, pp.94-95, 2003.
DOI : 10.1093/jnci/95.2.94

C. Holschneider and J. Berek, Ovarian cancer: Epidemiology, biology, and prognostic factors, Seminars in Surgical Oncology, vol.93, issue.2, pp.3-10, 2000.
DOI : 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S

W. Mcguire, M. Brady, and R. Ozols, The gynecologic oncology group experience in ovarian cancer, Annals of Oncology, vol.10, issue.+1, pp.29-34, 1999.
DOI : 10.1023/A:1008303300675

W. Mcguire, W. Hoskins, M. Brady, P. Kucera, E. Partridge et al., Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer, New England Journal of Medicine, vol.334, issue.1, pp.1-6, 1996.
DOI : 10.1056/NEJM199601043340101

M. Piccart, K. Bertelsen, K. James, J. Cassidy, C. Mangioni et al., Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results, Journal of the National Cancer Institute, vol.92, issue.9, pp.699-708, 2000.
DOI : 10.1093/jnci/92.9.699

B. Behrens, T. Hamilton, H. Masuda, K. Grotzinger, J. Whang-peng et al., Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues, Cancer Res, vol.47, pp.414-418, 1987.

L. Levin and W. Hryniuk, Dose intensity analysis of chemotherapy regimens in ovarian carcinoma., Journal of Clinical Oncology, vol.5, issue.5, pp.756-767, 1987.
DOI : 10.1200/JCO.1987.5.5.756

L. Levin, R. Simon, and W. Hryniuk, Importance of Multiagent Chemotherapy Regimens in Ovarian Carcinoma: Dose Intensity Analysis, JNCI Journal of the National Cancer Institute, vol.85, issue.21, pp.1732-1742, 1993.
DOI : 10.1093/jnci/85.21.1732

J. Dauplat, M. Legros, P. Condat, J. Ferriere, B. Ahmed et al., High-dose melphalan and autologous bone marrow support for treatment of ovarian carcinoma with positive second-look operation, Gynecologic Oncology, vol.34, issue.3, pp.294-298, 1987.
DOI : 10.1016/0090-8258(89)90161-3

P. Viens, D. Maraninchi, M. Legros, F. Oberling, T. Philip et al., High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France, Bone Marrow Transplant, vol.5, pp.227-233, 1990.

F. Bertucci, P. Viens, J. Delpero, V. Bardou, C. Faucher et al., High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results, Bone Marrow Transplantation, vol.26, issue.1, pp.61-67, 2000.
DOI : 10.1038/sj.bmt.1702468

F. Viret, F. Bertucci, D. Genre, G. Gravis, C. Chabannon et al., Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study, Bone Marrow Transplantation, vol.30, issue.12, pp.879-884, 2000.
DOI : 10.1038/sj.bmt.1703762

C. Papadimitriou, U. Dafni, A. Anagnostopoulos, G. Vlachos, Z. Voulgaris et al., High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial, Bone Marrow Transplantation, vol.23, issue.6, pp.547-554, 2008.
DOI : 10.1002/1097-0142(19841201)54:2+<2706::AID-CNCR2820541417>3.0.CO;2-L

V. Möbus, H. Wandt, N. Frickhofen, C. Bengala, K. Champion et al., Phase III Trial of High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First-Line Treatment of Advanced Ovarian Cancer: Intergroup Trial of the AGO-Ovar/AIO and EBMT, Journal of Clinical Oncology, vol.25, issue.27, pp.4187-4193, 2007.
DOI : 10.1200/JCO.2006.09.7527

F. Bertucci, C. Tarpin, E. Charafe-jauffret, V. Bardou, A. Braud et al., Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment, Bone Marrow Transplantation, vol.33, issue.9, pp.913-920, 2004.
DOI : 10.1038/sj.bmt.1704458

P. Viens, C. Tarpin, H. Roche, and F. Bertucci, Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies, Cancer, vol.95, issue.suppl, pp.2829-2836, 2010.
DOI : 10.1002/cncr.25168

A. Zander, C. Schmoor, N. Kröger, W. Krüger, V. Möbus et al., Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up, Annals of Oncology, vol.19, issue.6, pp.1082-1089, 2008.
DOI : 10.1093/annonc/mdn023

P. Biron, M. Durand, H. Roché, T. Delozier, C. Battista et al., Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer, Bone Marrow Transplantation, vol.15, issue.6, pp.555-562, 2008.
DOI : 10.1200/JCO.2005.11.029

D. Berry, N. Ueno, M. Johnson, X. Lei, J. Caputo et al., High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials, Journal of Clinical Oncology, vol.29, issue.24, pp.3214-3223, 2011.
DOI : 10.1200/JCO.2010.32.5910

J. Hartmann, T. Gauler, B. Metzner, A. Gerl, J. Casper et al., Phase I/II Study of Sequential Dose-Intensified Ifosfamide, Cisplatin, and Etoposide Plus Paclitaxel As Induction Chemotherapy for Poor Prognosis Germ Cell Tumors by the German Testicular Cancer Study Group, Journal of Clinical Oncology, vol.25, issue.36, pp.742-5747, 2007.
DOI : 10.1200/JCO.2007.11.9099

A. Gonçalves, R. Delva, M. Fabbro, L. Gladieff, J. Lotz et al., Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study, Bone Marrow Transplantation, vol.23, issue.7, pp.651-659, 2006.
DOI : 10.1038/sj.bmt.1705302

P. Viens, F. Bertucci, G. Gravis, J. Camerlo, D. Cowen et al., Intensive chemotherapy with autologous stem cell transplantation in ovarian cancers: analysis of 67 patients treated at the Paoli-Calmettes Institute and a review of the literature, Bull Cancer, vol.9, pp.869-876, 1997.

H. Cure, C. Battista, J. Guastalla, M. Fabbro, N. Tubiana-mathieu et al., Phase III Randomized Trial of High-Dose Chemotherapy (HDC) and Peripheral Blood Stem Cell (PBSC) Support as Consolidation in Patients (pts) with Responsive Low-Burden Advanced Ovarian Cancer (AOC): Preliminary Results of a GINECO/ FNCLCC/ SFGM-TC Study, Proc Am Soc Clin Oncol, p.20, 2001.

M. Legros, J. Dauplat, J. Fleury, H. Cure, F. Suzanne et al., High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results., Journal of Clinical Oncology, vol.15, issue.4, pp.1302-1308, 1997.
DOI : 10.1200/JCO.1997.15.4.1302

P. Stiff, R. Bayer, C. Kerger, R. Potkul, D. Malhotra et al., High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients., Journal of Clinical Oncology, vol.15, issue.4, pp.13092-1317, 1997.
DOI : 10.1200/JCO.1997.15.4.1309

P. Stiff, E. Shpall, P. Liu, S. Wilczynski, N. Callander et al., Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study, Gynecologic Oncology, vol.94, issue.1, pp.98-106, 2004.
DOI : 10.1016/j.ygyno.2004.02.032

T. Pal, J. Permuth-wey, J. Betts, J. Krischer, J. Fiorica et al., mutations account for a large proportion of ovarian carcinoma cases, Cancer, vol.283, issue.4 Suppl, pp.2807-2816, 2005.
DOI : 10.1002/cncr.21536

J. Boyd, Y. Sonoda, M. Federici, F. Bogomolniy, E. Rhei et al., Clinicopathologic Features of <EMPH TYPE="ITAL">BRCA</EMPH>-Linked and Sporadic Ovarian Cancer, JAMA, vol.283, issue.17, pp.2260-2265, 2000.
DOI : 10.1001/jama.283.17.2260

P. Vencken, M. Kriege, D. Hoogwerf, S. Beugelink, M. Van-der-burg et al., Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients, Annals of Oncology, vol.22, issue.6, pp.1346-1352, 2011.
DOI : 10.1093/annonc/mdq628

D. Tan, C. Rothermundt, K. Thomas, E. Bancroft, R. Eeles et al., Mutations, Journal of Clinical Oncology, vol.26, issue.34, pp.5530-5536, 2008.
DOI : 10.1200/JCO.2008.16.1703
URL : https://hal.archives-ouvertes.fr/hal-01388447

P. Konstantinopoulos, D. Spentzos, B. Karlan, T. Taniguchi, E. Fountzilas et al., ness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer, Journal of Clinical Oncology, vol.28, issue.22, pp.3555-3561, 2010.
DOI : 10.1200/JCO.2009.27.5719

R. Bast, . Jr, and G. Mills, ness and Beyond, Journal of Clinical Oncology, vol.28, issue.22, pp.3545-3548, 2010.
DOI : 10.1200/JCO.2010.28.5791

P. Fong, D. Boss, T. Yap, A. Tutt, P. Wu et al., Mutation Carriers, New England Journal of Medicine, vol.361, issue.2, pp.123-134, 2009.
DOI : 10.1056/NEJMoa0900212

P. Fong, T. Yap, D. Boss, C. Carden, M. Mergui-roelvink et al., Carrier Ovarian Cancer Correlating With Platinum-Free Interval, Journal of Clinical Oncology, vol.28, issue.15, pp.2512-2519, 2010.
DOI : 10.1200/JCO.2009.26.9589

M. Audeh, J. Carmichael, R. Penson, M. Friedlander, B. Powell et al., Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial, The Lancet, vol.376, issue.9737, pp.245-251, 2010.
DOI : 10.1016/S0140-6736(10)60893-8

K. Gelmon, H. Hirte, A. Robidoux, K. Tonkin, M. Tischkowitz et al., Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study, The Lancet Oncology, vol.12, issue.9, pp.852-861, 2011.
DOI : 10.1016/S1470-2045(11)70214-5

M. Piccart, A. Floquet, G. Scarfone, P. Willemse, J. Emerich et al., Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy, International Journal of Gynecological Cancer, vol.13, issue.s2, pp.13196-203, 2003.
DOI : 10.1111/j.1525-1438.2003.13360.x

S. Pecorelli, G. Favalli, A. Gadducci, D. Katsaros, P. Panici et al., Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1, Journal of Clinical Oncology, vol.27, issue.28, pp.4642-4648, 2009.
DOI : 10.1200/JCO.2009.21.9691

T. Perren, A. Swart, J. Pfisterer, J. Ledermann, E. Pujade-lauraine et al., A Phase 3 Trial of Bevacizumab in Ovarian Cancer, New England Journal of Medicine, vol.365, issue.26, pp.2484-96, 2011.
DOI : 10.1056/NEJMoa1103799